Loading...
XSHE
002019
Market cap1.77bUSD
Jul 10, Last price  
9.87CNY
1D
1.54%
1Q
-21.60%
Jan 2017
-35.45%
IPO
721.67%
Name

Yifan Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002019 chart
P/E
29.86
P/S
2.34
EPS
0.33
Div Yield, %
1.01%
Shrs. gr., 5y
-0.12%
Rev. gr., 5y
-1.01%
Revenues
5.13b
-0.52%
346,404,621764,741,628479,922,561405,987,288379,884,873495,734,761644,191,1391,158,213,8401,684,984,3642,434,929,7653,504,600,9524,373,293,9784,631,795,4395,186,843,6365,400,380,5804,409,035,5853,836,640,7994,068,107,3335,159,823,2275,132,949,329
Net income
402m
+4.16%
8,729,789240,189,33641,237,02830,369,566-197,551,804-230,291,29214,318,696117,646,250237,909,179360,573,507704,762,7331,305,103,515737,436,712903,467,857968,390,566278,398,957191,217,987-551,073,062385,967,575402,021,183
CFO
458m
-28.46%
32,616,424248,705,17283,307,29658,612,209-33,824,947-52,822,77829,881,96734,319,558139,735,191401,960,150855,845,8351,132,728,6031,170,900,515937,240,4201,108,506,411301,231,402472,065,141348,584,791640,730,192458,366,284
Dividend
May 29, 20250.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, sale of pharmaceutical products, active pharmaceutical ingredients and polymer materials. It provides blood tumors, gynecology, pediatrics, skin, orthopedic drugs, phosphate buffered saline, polyvinyl butyral products, vitamin B5 and original B5. The company was founded on November 10, 2000 and is headquartered in Hangzhou, China.
IPO date
Jul 13, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT